687 related articles for article (PubMed ID: 14963199)
1. Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review.
Whittle SL; Hughes RA
Rheumatology (Oxford); 2004 Mar; 43(3):267-71. PubMed ID: 14963199
[TBL] [Abstract][Full Text] [Related]
2. Hyperhomocysteinemia in rheumatoid arthritis: influence of methotrexate treatment and folic acid supplementation.
Jensen OK; Rasmussen C; Mollerup F; Christensen PB; Hansen H; Ekelund S; Thulstrup AM
J Rheumatol; 2002 Aug; 29(8):1615-8. PubMed ID: 12180718
[TBL] [Abstract][Full Text] [Related]
3. Folic acid supplementation prevents deficient blood folate levels and hyperhomocysteinemia during longterm, low dose methotrexate therapy for rheumatoid arthritis: implications for cardiovascular disease prevention.
Morgan SL; Baggott JE; Lee JY; Alarcón GS
J Rheumatol; 1998 Mar; 25(3):441-6. PubMed ID: 9517760
[TBL] [Abstract][Full Text] [Related]
4. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis.
Shea B; Swinden MV; Tanjong Ghogomu E; Ortiz Z; Katchamart W; Rader T; Bombardier C; Wells GA; Tugwell P
Cochrane Database Syst Rev; 2013 May; 2013(5):CD000951. PubMed ID: 23728635
[TBL] [Abstract][Full Text] [Related]
5. Folate, homocysteine, and cobalamin status in patients with rheumatoid arthritis treated with methotrexate, and the effect of low dose folic acid supplement.
Hornung N; Ellingsen T; Stengaard-Pedersen K; Poulsen JH
J Rheumatol; 2004 Dec; 31(12):2374-81. PubMed ID: 15570637
[TBL] [Abstract][Full Text] [Related]
6. Reduced folate carrier-1 80G>A polymorphism affects methotrexate treatment outcome in rheumatoid arthritis.
Drozdzik M; Rudas T; Pawlik A; Gornik W; Kurzawski M; Herczynska M
Pharmacogenomics J; 2007 Dec; 7(6):404-7. PubMed ID: 17325736
[TBL] [Abstract][Full Text] [Related]
7. [Reducing toxicity of methotrexate with folic acid].
Harten P
Z Rheumatol; 2005 Jun; 64(5):353-8. PubMed ID: 15965822
[TBL] [Abstract][Full Text] [Related]
8. Intermittent rises in plasma homocysteine in patients with rheumatoid arthritis treated with higher dose methotrexate.
Hoekstra M; Haagsma CJ; Doelman CJ; van de Laar MA
Ann Rheum Dis; 2005 Jan; 64(1):141-3. PubMed ID: 15608313
[TBL] [Abstract][Full Text] [Related]
9. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis.
Ortiz Z; Shea B; Suarez Almazor M; Moher D; Wells G; Tugwell P
Cochrane Database Syst Rev; 2000; (2):CD000951. PubMed ID: 10796393
[TBL] [Abstract][Full Text] [Related]
10. Reduction of the efficacy of methotrexate by the use of folic acid: post hoc analysis from two randomized controlled studies.
Khanna D; Park GS; Paulus HE; Simpson KM; Elashoff D; Cohen SB; Emery P; Dorrier C; Furst DE
Arthritis Rheum; 2005 Oct; 52(10):3030-8. PubMed ID: 16200612
[TBL] [Abstract][Full Text] [Related]
11. Folate supplementation during methotrexate therapy for patients with psoriasis.
Strober BE; Menon K
J Am Acad Dermatol; 2005 Oct; 53(4):652-9. PubMed ID: 16198787
[TBL] [Abstract][Full Text] [Related]
12. [Methotrexate and folates in rheumatoid arthritis].
Endresen GK; Husby G
Tidsskr Nor Laegeforen; 1999 Feb; 119(4):534-7. PubMed ID: 10081378
[TBL] [Abstract][Full Text] [Related]
13. Economic evaluation of folate supplementation during methotrexate treatment in rheumatoid arthritis.
Hartman M; van Ede A; Severens JL; Laan RF; van de Putte L; van der Wilt GJ
J Rheumatol; 2004 May; 31(5):902-8. PubMed ID: 15124248
[TBL] [Abstract][Full Text] [Related]
14. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis.
Prodanovich S; Ma F; Taylor JR; Pezon C; Fasihi T; Kirsner RS
J Am Acad Dermatol; 2005 Feb; 52(2):262-7. PubMed ID: 15692471
[TBL] [Abstract][Full Text] [Related]
15. Risk factors associated with the cumulative survival of low-dose methotrexate in 273 Japanese patients with rheumatoid arthritis.
Ideguchi H; Ohno S; Ishigatsubo Y
J Clin Rheumatol; 2007 Apr; 13(2):73-8. PubMed ID: 17414533
[TBL] [Abstract][Full Text] [Related]
16. [Correct use of methotrexate].
Verduijn MM; van den Bemt BJ; Dijkmans BA; van der Waal RI; Horikx A
Ned Tijdschr Geneeskd; 2009; 153():A696. PubMed ID: 19785852
[TBL] [Abstract][Full Text] [Related]
17. The effect of folic acid and folinic acid supplements on purine metabolism in methotrexate-treated rheumatoid arthritis.
Morgan SL; Oster RA; Lee JY; Alarcón GS; Baggott JE
Arthritis Rheum; 2004 Oct; 50(10):3104-11. PubMed ID: 15476202
[TBL] [Abstract][Full Text] [Related]
18. Controlled trial of methotrexate versus CH-1504 in the treatment of rheumatoid arthritis.
Castaneda O; Nair MG
J Rheumatol; 2006 May; 33(5):862-4. PubMed ID: 16652417
[TBL] [Abstract][Full Text] [Related]
19. Risk factors for methotrexate-induced abnormal laboratory monitoring results in patients with rheumatoid arthritis.
Kent PD; Luthra HS; Michet C
J Rheumatol; 2004 Sep; 31(9):1727-31. PubMed ID: 15338491
[TBL] [Abstract][Full Text] [Related]
20. Methotrexate polyglutamate concentrations are not associated with disease control in rheumatoid arthritis patients receiving long-term methotrexate therapy.
Stamp LK; O'Donnell JL; Chapman PT; Zhang M; James J; Frampton C; Barclay ML
Arthritis Rheum; 2010 Feb; 62(2):359-68. PubMed ID: 20112376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
